Hg, the Manager of HgCapital Trust plc (“HGT”), today announces that it has agreed the sale of MEDIFOX DAN, a leading provider of digital solutions for the German care and therapy sectors, to ResMed, a global leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, in a transaction valuing the business at an enterprise value of around US $1 billion.

The terms of the transaction have not been disclosed and completion is subject to closing conditions.

HGT, whose shares are listed on the London Stock Exchange, gives private and institutional investors the opportunity to participate in all Hg’s investments.

This transaction values HGT’s investment in MEDIFOX DAN at approximately £47.3 million. This would represent an uplift of £14.6 million (45% or 3.2 pence per share) over the carrying value of £32.7 million in the Net Asset Value (“NAV”) of HGT at 31 March 2022.

Note that these figures only relate to HgCapital Trust’s share of Hg’s overall investment in MEDIFOX DAN.

Based on the 31 March 2022 reported NAV, the pro-forma NAV of the Trust is expected to be £2.1 billion (or 454.9 pence per share). HGT’s available liquid resources, which includes the undrawn bank facility of £250 million for future deployment (including all announced transactions) are estimated to be £476 million (23% of the pro-forma 31 March 2022 NAV).

Hg agrees sale of MEDIFOX DAN to ResMed for US$1bn

• Since 2018 Hg has supported MEDIFOX DAN to establish itself as a leading provider of digital solutions for the German care, support and therapy sectors, driven by a focus on the customer, continuous innovation and nine strategic acquisitions.
• Hg continues to be active in the healthcare technology sector, having signed transactions in the sector worth over $6 billion in Enterprise Value in the last 12 months.

Hg, a leading software and services investor, today announces the sale of MEDIFOX DAN, a leading provider of digital solutions for the German care and therapy sectors, to ResMed, a global leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, in a transaction valuing the business at an enterprise value of around US $1 billion.

Founded in 1994 and headquartered in Hildesheim, Germany, MEDIFOX DAN is a leading provider of software solutions and services to care and therapy providers. Its core offering comprises digital solutions for resource and route planning, care planning & documentation, administration, and billing, as well as factoring and hosting services.

The group has more than 600 employees across eight locations in Germany. More than 300,000 caregivers trust in the innovation and quality delivered by one of the largest R&D teams in the industry.

Under the leadership of Dr. Thorsten Schliebe and Christian Städtler and with support from Hg, MEDIFOX DAN has demonstrated an impressive evolution, continuously expanding its product & services offering, entering attractive new segments, strengthening the wider management team, investing into a state-of-the-art system landscape and digital sales capabilities as well as driving strategic acquisitions. MEDIFOX DAN has also just announced the launch of its new cloud-ready software generation PROXIMA – combining the best of both worlds of MEDIFOX and DAN.

ResMed is a world-leading digital health company. Its pioneering cloud-connected medical devices and out-of-hospital software solutions have transformed care for over 137 million people globally. ResMed is also a leader in mission-critical enterprise software and services for the out-of-hospital care sector, serving homecare provider, stationary and ambulatory care equivalent sectors in the United States.

By joining forces through an acquisition of MEDIFOX DAN, ResMed expands its SaaS business footprint outside the U.S. and will be uniquely positioned to accelerate the digital transformation of care in Germany.

Dr. Thorsten Schliebe and Christian Städtler, Co-Managing Directors of MEDIFOX DAN, said: “MEDIFOX DAN cares about the people who care for people. We think partnering with ResMed, one of the leaders of our sector, is a unique opportunity to deliver upon that promise and on a much wider scale. We are excited to take this next step of the journey together and to continue delivering the best solutions and innovation to our clients. We want to thank the Hg team for sharing our entrepreneurial vision and offering their relentless support over the last few years, helping MEDIFOX DAN to become the best version of this vision.”

Stefan Margolis and Benedikt Joeris, both Partners at Hg, said: “It has been a great journey and partnership with Thorsten, Christian and the whole MEDIFOX DAN team. We had long-recognised MEDIFOX as a high-quality software business, providing crucial services to integrated care. Together we have significantly further expanded MEDIFOX DAN’s offering through continued product investment, including nine acquisitions. ResMed, who we’ve known for many years, will be a great home to continue that innovation journey, enabling care givers to focus on people and patients.”

“With the acquisition of MEDIFOX DAN, a fast-growing and innovative German healthcare software leader, we will expand ResMed’s SaaS business portfolio outside our current base in the U.S. and strengthen our position as a global leader in healthcare software solutions for lower-cost and lower-acuity care” said ResMed CEO Mick Farrell. “We are excited to welcome the MEDIFOX DAN team to our global ResMed family: Our management cultures are highly aligned with a laser-focus on lowering costs, improving outcomes, and changing the course of chronic disease management. MEDIFOX DAN has a strong track record of innovation, fully aligned with our teams at Brightree, MatrixCare, and beyond. MEDIFOX DAN’s customer centricity has built strong and ongoing, growing demand for its software solutions across Germany, and we expect that momentum to continue and strengthen as we become one global team. Our MEDIFOX DAN and ResMed teams are united with the same global mission: to help many hundreds of millions of people live healthier lives outside the hospital, and preferably in their own home.”

The terms of the transaction have not been disclosed and completion is subject to closing conditions.

Below is a short animated clip highlighting the key points from the Year End Results